Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria.

Nichimura, Jun-Ichi, Ando, Kiyoshi, Masuko, Masayoshi, Noji, Hideyoshi, Ito, Yoshikazu, Mayer, Jiri, Griskevicius, Laimonas, Bucher, Christoph, Muellershausen, Florian, Gergely, Peter, Rozenberg, Izabela, Schubart Wellensiek, Anna, Chawla, Raghav, Rondeau, Jean-Michel, Roguska, Michael, Splawski, Igor, Keating, Mark, Johnson, Leslie, Danekula, Rambabu, Bagger, Morten, WATANABE, YOKO, Haraldsson, Boerje and Kanakura, Yuzuru (2022) Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria. Haematologica, 107 (6). pp. 1483-1488.

Abstract

Not available.

Item Type: Article
Date Deposited: 11 Oct 2022 00:46
Last Modified: 11 Oct 2022 00:46
URI: https://oak.novartis.com/id/eprint/46966

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.